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Abstract
Cardiovascular disease and hypertension are leading causes of death worldwide. 
The mitigation of high blood pressure is essential in decreasing the prevalence of 
cardiovascular-related deaths worldwide. Stress and anxiety are known to play a role in 
augmenting blood pressure in individuals of all ages. This increase in pressure can result 
in premature stiffening of large arteries in systemic circulation. Mindfulness is an ancient, 
non-secular practice which aids in stress reduction. Decentering, an aspect of 
mindfulness, involves accepting thoughts as transient rather than permanent associations. 
The purpose of this project was to examine the relationship between cardiovascular 
health and mindfulness practices. In Study 1, we investigated how a one-hour session of 
mindfulness meditation affected arterial stiffness and other cardiovascular variables. In 
Study 2, we compared inexperienced meditators’ inherent ability to decenter with their 
arterial stiffness. We hypothesized that an acute meditation session would improve 
cardiovascular variables in Study 1. In Study 2, we postulated that individuals who are 
better able to decenter would have a slower pulse wave velocity and more elastic arteries. 
Our results from Study 1 suggest that an acute session of meditation can significantly 
decrease aortic pulsatile load. In Study 2, we concluded that a greater ability to decenter 
is correlated with slower pulse wave velocity. These new findings support many previous 
studies that suggest that mindfulness practices are a beneficial lifestyle modification that 
can positively impact cardiovascular health. 
x
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1. Literature Review
The literature review of this thesis aims to first provide a brief synopsis of 
cardiovascular health and hypertension, the effect of stress and anxiety on the 
cardiovascular system, and the associated physiological mechanisms of the stress 
response. A short summary of the current knowledge of aortic stiffness, the systemic 
effects of arterial stiffness, wave reflection, and the associated measurement variables 
will be discussed. Then, a general overview of mindfulness meditation, including the 
efficacy of acute practices and decentering, will be presented. Finally, the literature 
review will include a general summary and proposed hypothesis for the two research 
studies. 
1.1 Cardiovascular Health and Hypertension 
Cardiovascular and other circulatory diseases are currently the most prevalent 
causes of death for people worldwide. Cardiovascular disease (CVD) plagues populations 
in all countries regardless of income. Between 1990 and 2013, individuals living in low- 
and middle-income countries (LMIC) experienced an increase in the proportion of deaths 
attributable to CVD at a younger age, while high-income countries (HIC) saw a slight 
decrease, likely due to improvements in primary and secondary prevention and care (62). 
Despite the trend, more individuals still die from CVD in HICs compared to LMICs.  
Hypertension is the number one attributable risk for death worldwide (13). In 
2017, the American Heart Association edited their guidelines for diagnosing 
hypertension. Elevated blood pressure is systolic blood pressure between 120-129 mmHg 
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and diastolic blood pressure less than 80 mmHg. Stage 1 hypertension includes systolic 
blood pressure between 130-139 mmHg and diastolic blood pressure between 80-89 
mmHg, while stage 2 hypertension is systolic pressure greater than 140 mmHg or 
diastolic greater than 90 mmHg.  
Suboptimal blood pressure has been associated with coronary artery disease, 
stroke, renal disease, and heart failure (15), making hypertension a multifaceted systemic 
pathology. Additionally, hypertension may also cause damage to the delicate 
microvasculature of target organs, which typically function at a lower resistance (68). 
Hypertension is often deemed the “silent killer,” as up to 30% of adults are unaware of 
having high blood pressure (13). This presents a variety of problems and an increased 
risk for individuals who may not regularly check their blood pressure. Some 
epidemiological predictors and risk factors for developing hypertension include obesity, 
high sodium intake, increased arterial stiffness, and uncontrolled stress (41, 68). 
In an attempt to mitigate the prevalence of hypertension and CVD-related deaths, 
the World Health Organization has set sustainable development goals with the intention 
of diminishing CVD-related deaths by 1/3 by the year 2030 (54). Other than 
pharmacological intervention and common lifestyle modifications such as exercise or 
diet, the maintenance of stress levels may be an appropriate adjunct treatment option for 
individuals with hypertension, which will be discussed in further detail later. 
1.1.1 Cardiovascular System and HPA Axis 
The stress response is an essential process in the human body. Evolutionarily, the 
cascade of events occurring during a stressful situation is physiologically necessary in 
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order to survive physical and dangerous threats (65). The hypothalamic-pituitary-adrenal 
(HPA) axis is an essential stress pathway which ultimately ends with the production and 
release of the glucocorticoid cortisol. Cortisol is an essential stress hormone that 
increases immediate energy availability in the body.  
 The mechanism of action for the HPA axis involves three primary structures: the 
hypothalamus, the pituitary gland, and the adrenal gland. In response to stressful stimuli, 
the hypothalamus releases corticotropin releasing hormone, which stimulates the anterior 
pituitary gland to secrete adrenocorticotropic hormone. This hormone stimulates the 
adrenal glands to release cortisol as a part of the stress response. 
While the release of cortisol is essential in an acute stress response, issues arise 
when there is prolonged release of cortisol due to chronic stress, including suppression of 
the immune system, impairment of glucagon and insulin secretion, increases in pro-
inflammatory cytokines, and increases in oxidative stress (23). An increase in 
inflammatory markers is an independent risk factor of premature death from 
cardiovascular disease (39). These cytokines, in conjunction with increased blood 
pressure from stress, can cause a multitude of negative effects in the vasculature, 
including endothelial damage, an atherosclerotic lipid profile, and smooth muscle cell 
hyperplasia (8). This, in turn, promotes atherosclerosis and increases in arterial stiffness.  
1.1.2 Cardiovascular Health, Stress, and Anxiety 
Acute and chronic psychosocial stressors are often associated with increased risk 
of cardiovascular events and hypertension (41, 59, 67). These stressors can include stress 
from work, life events (such as the death of a family member), anxiety, and emotional 
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regulation. Additionally, coping strategies may influence the impact of these life stressors 
(20). From a meta-analysis, individuals who reported elevated perceived stress had a 27% 
higher risk of CHD than those who had lower perceived stress (59). Stress from work, 
social isolation, and emotional stress is associated with an increased relative risk of CHD, 
as well as the risk for triggering acute cardiac events such as myocardial infarction (67). 
Life stress is also correlated with increases in arterial stiffness, partly due to the 
development of anxiety or depressive disorders (9).  
Anxiety, specifically trait anxiety, has been strongly and positively correlated 
with hypertension (30, 40, 41). In fact, this association may be bidirectional - those with 
hypertension are more likely to have anxiety, while individuals with anxiety are more 
likely to be hypertensive (41). Anxiety is thought to affect cardiovascular health 
primarily through the HPA axis and increased sympathetic response, which leads to a 
cascade of physiological events including the increased release of stress hormones 
(catecholamines), endothelial damage, hypertension, atherosclerosis, and CHD (14). In 
hypertensive individuals, trait anxiety was positively correlated with elevated blood 
pressure (40) as well as emotional reactivity (30). These associations provide insight on 
the potential impact anxiety may have on the cardiovascular system. 
In addition to stress and anxiety, unregulated emotional response may affect 
cardiovascular health. Previous survivors of acute myocardial infarction who scored 
higher in state and trait anger (anger as an emotional response and as a personality trait, 
respectively) were statistically more at risk of myocardial ischemia from emotional stress 
(56). In healthy females, higher anger scores were predictive of increased mean blood 
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pressure and ambulatory arterial stiffness (44), which indicates that effectively targeting 
the mitigation of anger may be a mode in which to reduce negative cardiovascular 
effects.  
Not only is the reduction of stress imperative, but the way in which it is done is 
also an important consideration. Task-oriented coping involves purposeful thought or 
planning to solve a problem, while emotional-orientated coping may include rumination 
and emotions oriented toward the individual rather than the problem. Individuals who 
utilize a task-oriented coping mechanism, considered to be a functional coping style, have 
a significantly lower risk of hypertension compared to those who use an emotional-
oriented style (20). Thus, developing positive, task-oriented coping methods in 
individuals may be a protective measure against hypertension. An example of a possible 
task-oriented coping strategy is mindfulness meditation, as individuals are tasked with the 
constant focus of the present moment. This link between psychological state and coping 
mechanism with CVD is an important focus for the continued effort to reduce the 
mortality of heart-related diseases. 
1.2 Aortic Stiffness 
 The arteries are both capacitance and resistance vessels in the body. They receive 
blood from the heart to deliver to tissues while also functioning as pressure regulators. 
Arteries have a thick tunica media layer which contains smooth muscle. In response to 
sympathetic stimulation these muscles contract, decreasing the diameter of the vessel 
lumen and therefore increasing hemodynamic pressure.  
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Large arteries, and the smaller more distal arterioles, have structural differences 
that relate to their specific functions. In particular, the large arteries (such as the proximal 
aorta) are composed of greater amounts of elastin while more distal vessels contain more 
of the stiffer collagen fibers (10). This leads to a phenomenon known as systolic pressure 
amplification. As the pulse wave moves through progressively smaller arteries and 
arterioles, systolic pressure increases which is demonstrated through increased systolic 
peaks on pressure waveforms (46).   
The elastin in the large arteries permits the vessels to expand in order to 
accommodate the blood received from the left ventricle during systole, then slowly 
recoils to propagate the steady flow of blood. This aids in mitigating excess pulsatility 
that would arise from the intermittent pumping of the left ventricle. This is a protective 
feature that supports the more delicate microvasculature of organs with high blood flow 
(i.e., kidney), as these structures typically function with lower arterial resistance (12). 
Arteries tend to progressively stiffen over time, a process that is considered a 
result of normal aging. This stiffening occurs linearly with age beginning in the 20-29 
Figure 1. Waveform differences throughout vasculature. As the pulse wave moves 
through smaller vessel lumens, there is an increase in the systolic pressure represented by 
the larger initial inflection point in the waveform. 
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year age group and continues to increase throughout life (1). The changes in arterial 
stiffness longitudinally are also associated with increases in systolic blood pressure, mean 
arterial pressure, and pulse pressure, with a decrease in diastolic blood pressure (15). 
However, the premature stiffening of large arteries is especially problematic, as the 
stiffening of the large arteries can lead to the development of systolic hypertension, 
increases in carotid intima-media thickness, decreases in coronary perfusion with 
increases in afterload, increases in the pulsatility experienced by the microvasculature, 
and other detrimental hemodynamic dysfunction (12, 68). The relationship with 
hypertension and arterial stiffness may also be bidirectional, as hypertension has been 
observed to accelerate aortic degeneration leading to similar pressure changes from 
normal aging (52). These developments can eventually lead to different pathologies in 
various systems. In the heart, arterial stiffness is associated with left ventricle 
hypertrophy, which is present in heart failure (72). Along with age, arterial stiffness can 
be influenced by smoking, high BMI, and inactivity (12, 43).  
Objectively quantifying the stiffness of large arteries is an early detectable way to 
assess structural and functional changes within vessel walls (10). Two of the most 
common and reliable methods to noninvasively measure the arterial pulse wave and 
arterial stiffness are through pulse wave analysis (PWA) and pulse wave velocity (PWV) 
via applanation tonometry. This will be discussed in further detail in the next headings. 
1.2.1 Aortic Wave Reflection (Pulse Wave Analysis) 
Forward traveling pulse waves from the left ventricle toward systemic circulation 
also transmit a reflected wave as pulses arrive at bifurcations or through changes in vessel 
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diameter and structural composition (12). In younger, healthy individuals, incident waves 
are reflected back toward the heart during diastole, which augments diastolic pressure 
(71). Reflected waves reaching the proximal aorta during diastole modulates an increase 
in myocardial perfusion, which aids the ability of oxygen rich blood to reach the heart 
muscle tissue. In people with stiff arteries, this pulse wave reflects backwards at a faster 
rate. This causes the reflected wave to reach the proximal aorta during the middle or end 
of systole, which augments systolic pressure and increases both pulse pressure and 
afterload (12, 24).  
Pulse wave analysis (PWA) is a noninvasive method to analyze aortic waveforms. 
According to O’Rourke et al., analyzing aortic pulse waves requires a calibrated system 
via supine brachial blood pressure readings, an accurate recording of the radial pulse 
wave, and the computer-generated aortic wave form using a generalized transfer function 
(52). In this way, investigators can get an accurate estimate of the aortic waveform 
noninvasively, using the radial artery as the site of application for applanation tonometry. 
9 
One important descriptive value from PWA is the aortic augmentation index 
(AIx), which is defined as the augmentation pressure divided by pulse pressure (72). 
Typically, AIx is expressed as a percentage of pulse pressure. Augmentation pressure 
(AP) is the extra pressure added to the initial systolic inflection point (incident wave) 
from the reflected wave in the aorta, which can be influenced by when reflected waves 
arrive (i.e., systole vs. diastole) (10, 52). Pulse pressure is calculated simply as systolic 
blood pressure minus diastolic blood pressure and is influenced by stroke volume and 
aortic stiffness (72). Pulse pressure (PP) can be calculated from brachial blood pressure 
Figure 2. A visual depiction of the aortic pulse wave highlighting the relationship 
between the incident pressure wave, augmentation pressure (AP) and pulse pressure 
(PP) (29).
10 
readings, but values from the SphygmoCor system provide trusted estimates of aortic 
pulse pressure which has even greater clinical relevance (33, 46).  
A final cardiovascular factor of importance relating to the pulse wave is aortic 
pulsatile load (aPL), defined as the product of heart rate and aortic pulse pressure (47). 
Pulsatile load describes the repetitive mechanical stress on arterial walls. Increases in PP, 
via an increase in SAP, influences the value of aPL. Over time, this increased stress can 
lead to elastin fatigue and smooth muscle hypertrophy and thus the development of stiffer 
arteries (32). Thus, increases in aPL can increase hemodynamic stress on end organs with 
delicate vasculature, such as the brain and kidneys. 
1.2.2 Pulse Wave Velocity 
Pulse wave velocity (PWV) is the gold standard method to assess and quantify 
arterial stiffness noninvasively as it is reproducible, simple, accurate, and robust (10). 
PWV is inversely related to the artery’s elasticity; that is, a stiffer artery will propagate 
the pulse wave faster than a more elastic artery (10). Notably, it is an independent and 
powerful predictor of cardiovascular risk and all-cause mortality (10, 12, 70). 
Specifically, a 1 m/s increase in PWV is reported to be associated with a 10% greater risk 
in CV mortality and all-cause mortality (70). PWV is also a reliable predictor of future 
systolic blood pressure changes and development of hypertension in healthy individuals 
(10). PWV is faster in individuals with hypertension (43), suggesting that those who are 
hypertensive may have stiffer, more inelastic central arteries regardless of age (18). 
Mechanistically, stiffer arteries and a faster PWV reduce coronary perfusion due to 
augmented systolic pressure, which can lead to myocardial dysfunction (12). Similar to 
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PWA, central PWV is most commonly and noninvasively measured via applanation 
tonometry at the carotid artery and femoral artery sites, otherwise known as carotid-
femoral PWV (cfPWV) (49).  
1.3 Mindfulness 
There is no one, current operational definition of mindfulness, although Jon 
Kabat-Zinn, a pioneer in current mindfulness practices and the founder of the 
mindfulness based stress reduction (MBSR) model, defines mindfulness as “the 
awareness that emerges through paying attention on purpose, in the present moment, and 
nonjudgmentally to the unfolding of experience moment by moment” (36). Mindfulness 
does not focus on changing the direct experience felt by an individual; rather, a key 
component of mindfulness is experiencing situations through non-judgmental awareness 
of the present moment and acceptance (11). Mindfulness practice can be considered a 
type of mental training with focus on reducing reactivity and similar states of mind that 
otherwise may perpetuate emotional distress (7).  
The central practice of mindfulness is seated mindfulness meditation, in which 
individuals focus inward, usually on some aspect of the physical self (i.e., breathing) to 
stay focused and anchored in the present moment. Throughout the meditation practice, 
the mind will inevitably wander from the breath, but the individual simply notices this 
and brings the awareness back to the breath without judgment or rumination. This formal 
practice sets the foundation for informal, here-and-now awareness throughout daily living 
(7). 
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Recently, mindfulness has drawn considerable interest within the scientific 
community due to a variety of psychological and behavioral benefits. While mindfulness 
research is still rampantly gaining popularity, previous studies have shown promising 
results. A primary goal of mindfulness programs is mitigation of stress reactivity. One 
study found meditation practices may reduce stress reactivity in at-risk stressed 
populations, which in turn, may reverse or mitigate disease outcomes related to high 
levels of physiological stress and arousal (7).  
Other studies have observed further benefits, including increases in attention post-
meditation (17), cooperation and altruism (31), as well as decreases in binge and 
emotional eating (37). The wide scope of benefits mindfulness can offer strengthens the 
argument that mindfulness may be a clinically relevant and useful tool to improve the 
health and well-being of all individuals. 
1.3.1. Mindfulness and Cardiovascular Health  
  Along with studied psychological benefits, mindfulness practices have proposed 
cardiovascular benefits. While mechanisms for the benefits of mindfulness on 
cardiovascular health are unknown, theoretical framework includes improved attentional 
control, improved emotional control, and self-awareness (42). These factors relate to the 
ability to enact and maintain beneficial lifestyle changes to improve health (i.e., quitting 
smoking). 
A physiological mechanism to consider is the hypothalamic-pituitary-adrenal 
(HPA) axis. The implementation of mindfulness programs may be an effective way to 
decrease effects of overactivity from the HPA axis via decreasing the severity of the 
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stress response. In individuals with hypertension, 8-weeks of an MBSR course 
significantly reduced clinical seated resting systolic and diastolic blood pressure (29, 57). 
In another study, decreases in blood pressure were related to the improvements in anxiety 
and stress levels, although primarily for diastolic blood pressure (57). 
Other potential mechanisms include slow breathing as a modulator for 
cardiovascular control (63). In formal mindfulness practices such as seated meditations 
and body scans, individuals are encouraged to deepen their breath and focus on how the 
breath feels as it is inhaled. Instructors may cue their participants to “send the breath” to 
specific areas of the body, such as the chest and belly, to provide more direct guidance on 
the sensation of the increased depth of breath. An assortment of previous studies have 
demonstrated a reduction in blood pressure, both in hypertensive (34) and healthy 
individuals (58) who undergo slow, controlled breathing practices. This breathing 
practice promotes the activation of the parasympathetic nervous system via the Vagus (X) 
nerve, resulting in vasodilation and therefore reductions in blood pressure (63).  
It is important to note that MBSR programs are not intended to be substitutes for 
medication, but rather an adjunct to potentially mitigate high blood pressure and other 
detrimental cardiovascular variables (29). A combination of pharmacological and 
nonpharmacological treatments is typically required for optimal blood pressure control 
(63). 
1.3.2 Acute Meditation 
 Most current mindfulness literature studies the effects of mindfulness meditation 
in the scope of longitudinal mindfulness training (i.e., MBSR). However, longitudinal 8-
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week courses are not always plausible due to socioeconomic barriers such as the 
extended time commitment, potential monetary cost of the program, and transportation 
issues. To make mindfulness practices more inclusive to a wider population, acute bouts 
of meditation may be a solution without the commitment to a longitudinal program.  
 Brief mindfulness meditation practices have demonstrated similar psychological 
mind-body benefits. Previous studies have indicated that brief meditation improved self-
reported psychological stress reactivity compared to a control group (75 minutes over 3 
days) (16), increased executive attentional control in inexperienced meditators (10 
minutes for 1 day) (51), decreases in the cortisol awakening response (360 minutes over 4 
days) (4), and reduced pain and state anxiety (60 minutes over 3 days) (74). Additionally, 
an hour of guided mindfulness meditation reduced anxiety and aortic pulsatile load in a 
small cohort of individuals with mild to moderate anxiety (19). These results are 
noteworthy in that they suggest even small bouts of mindfulness meditation can 
positively influence an individual’s health and wellbeing. While these psychological 
benefits are clear, there is limited literature discussing how a short practice of 
mindfulness meditation may influence physiological variables of the cardiovascular 
system such as arterial stiffness. 
1.4 Decentering 
 Decentering is an aspect of mindfulness in which distant perspectives of thoughts 
and emotions are adopted. To analyze decentering, three proposed interrelated processes 
involving metacognition were developed (6). These processes include meta-awareness, or 
the awareness that thoughts or feelings are occurring; disidentification from internal 
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experience, or being able to separate oneself from internal states; and reduced reactivity 
to thought content, or demonstrating a diminished rumination of thoughts (5). In this way, 
decentering can be simply defined as understanding thoughts and emotions as transient, 
rather than permanent associations of oneself and accepting an objective perspective. For 
example, a distanced stance of emotions would be demonstrated by the statement, “I am 
aware I am feeling sadness,” as opposed to “I am sad.” This thought pattern dissociates 
negative feelings and emotions from the individual. Decentering, similar to other skills, 
can be improved with practice. Mindfulness practices, especially formal MBSR courses, 
can improve an individual’s ability to decenter and improve overall life satisfaction (26, 
28, 64).  
 The most commonly used method to measure the ability to decenter (trait 
decentering) is the Experiences Questionnaire (EQ) from David Fresco. The EQ is an 11-
item questionnaire based on a Likert-type scale, with responses ranging from 1 (never or 
rarely true) to 5 (often or always true). This questionnaire measures the extent to which 
an individual can decenter in three ways: the ability to dissociate from thoughts, the 
ability to demonstrate self-compassion, and the ability to avoid habitual responses to 
negative stimuli (22). The EQ demonstrates good internal consistency with Cronbach’s 
alpha of 0.83 (22). Additionally, the EQ performs similarly across a variety of factors, 
including sex, age, ethnicity/race, and previous meditation experience, suggesting that it 
provides an unbiased and comparable measurement of decentering among a diverse 
cohort (48). 
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1.4.1 Decentering and Anxiety 
Enhancements in decentering via formal MBSR courses have been associated 
with a variety of health benefits, including an increased acceptance of pain (45), a 
decrease in depressive symptoms (38), and a reduction in anxiety symptoms (25-27). 
Improvements in all aspects of mindfulness typically occur, but anxiety tends to correlate 
specifically with decentering (25-27). While most of the causal mechanisms behind 
improved decentering remain unknown, a variety of studies have found an association 
between increases in decentering with lower anxiety scores.  
Recently, decentering has been used as a tool in a variety of cognitive therapies 
for individuals suffering from anxiety disorders, such as generalized anxiety disorder 
(GAD), including emotion relation therapy and cognitive behavioral therapies. Hoge et 
al., concluded that individuals suffering from GAD who underwent a modified MBSR 
course showed a decrease in physiological anxiety symptoms, which was associated with 
an increase in decentering (26). Further research found similar results in GAD patients 
undergoing emotional regulation therapy without a formal MBSR course (53). These 
findings suggest the improvement of decentering may provide significant relief in anxiety 
and its associated symptoms. 
1.4.2 Anxiety Inventories 
Self-reported anxiety inventories are imperative for establishing objective anxiety 
values from individuals. These inventories are especially useful for evidence-based 
medicine and can aid physicians in the screening of mental disorders, including anxiety 
disorders, by assessing self-reported symptoms (61). To validate these screening tools, 
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Cronbach’s alpha is used to determine the validity, comparability, and internal 
consistency of each psychometric inventory. Two of the most well-known and 
implemented inventories include the State Trait Anxiety Inventory (STAI) and the Beck 
Anxiety Inventory (BAI). 
Charles Spielberger’s STAI is an inventory that assesses both state anxiety and 
trait anxiety. State anxiety is defined as how the patient feels right now, in this moment. 
Trait anxiety relates to how an individual generally feels on a day-to-day basis. State and 
trait anxiety are polled on two separate forms. They are both 20-item questionnaires 
scored on a Likert-type scale, ranging from 1 (not at all) to 4 (very much so). When 
comparing psychometric inventories, the STAI’s internal consistency reliabilities were 
stable, especially that of the state anxiety scale, suggesting a reliable objectification of 
anxiety (2). Cronbach’s alpha for these questionnaires ranged from 0.86-0.95 (35). 
The BAI is a 21-item questionnaire that explores how much a patient has been 
bothered by anxiety-related symptoms over the past week. The BAI is scored on a 4-point 
Likert-type scale from 0 (not at all) to 3 (severely). Individuals who scored below 36 had 
low to moderate anxiety, while a score of 36 or above suggested high levels of anxiety. 
The reliability for this psychometric inventory is excellent, determined by a high 
Cronbach’s alpha between 0.90-0.94 (35).  
1.5 Summary and Hypothesis 
 In summary, CVD and hypertension account for the greatest number of deaths 
worldwide. Stress and anxiety are associated with a physiological role in the stress 
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response, which can contribute to the prevalence of hypertension and arterial stiffness. 
Measuring arterial stiffness is a reliable, noninvasive way to accurately estimate the 
stiffness of the aorta and central arteries via PWA and PWV, which are independent 
predictors of cardiovascular mortality. 
Mindfulness meditation, an ancient stress relief practice, may be a viable method 
to reduce stress and improve a variety of cardiovascular variables. Even short durations 
of mindfulness meditation are correlated with various psychosocial improvements. 
Decentering, an aspect of mindfulness, can be improved through mindfulness practices 
and is associated with decreased levels of stress and anxiety.  
For Study 1, we hypothesized that a one-hour session of acute meditation would 
decrease state anxiety and cardiovascular variables such as aPL, PWV, and AIx when 
comparing pre-intervention to post-intervention data. For Study 2, we hypothesized that 
individuals inexperienced in mindfulness practices who have a greater ability to decenter 
would have a slower pulse wave velocity and thus more elastic arteries. 
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2. Study 1: Acute Meditation 
2.1 Introduction 
Cardiovascular diseases (CVDs) are chronic diseases relating to the heart and 
vasculature that will kill up to an estimated 23.6 million people per year by 2030 (21). 
One of the most important risk factors for cardiovascular disease is hypertension (55). In 
particular, younger, college-aged subjects with slightly elevated blood pressure are three 
times more likely to develop hypertension later in life (50). This increase in blood 
pressure above normotensive levels can significantly and negatively impact the heart and 
vasculature at a younger age. Specifically, the premature stiffening of large arteries can 
lead to incident hypertension, damage to the microvasculature of organs, and increase left 
ventricle strain (12, 47, 65). These effects are also amplified by increases in pulsatility 
(47).  
 Previous studies have concluded that amplified levels of psychological stress and 
anxiety are associated with increases in blood pressure (41, 59, 67). Therefore, the 
reduction of stress may be an appropriate measure to help decrease and control blood 
pressure, and thus improve cardiovascular health. Mindfulness practices, such as 
mindfulness meditation, have been highlighted recently for their studied improvements in 
psychological variables such as anxiety (9).  
While previous longitudinal studies have been conducted related to mindfulness, 
there is less data on the impact of a shorter, acute meditation intervention on 
cardiovascular health. In fact, while a variety of mindfulness studies have been 
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conducted, very few have a focus on the potential physiological effects. Currently, it is 
not well known how a one-hour session of acute meditation may impact arterial stiffness. 
We hypothesized that reductions would occur between pre-intervention and post-
intervention trials in regard to anxiety, pulse wave velocity, aortic pulsatile load, and 
aortic augmentation index.  
2.2 Methods 
All testing took place in the Clinical and Applied Human Physiology Laboratory 
in the Biological Sciences department at Michigan Technological University.  
2.2.1 Subjects 
Thirteen (13) individuals ranging from 18 to 28 years of age volunteered to 
participate in this study. Eight females (22 ± 1 years old) and five males (20 ± 1 years 
old) were enrolled. Volunteers were recruited primarily by email and flyer. To participate 
in this study, individuals had to not be pregnant, not be taking cardiovascular medication, 
have no history of diabetes, not smoke or vape, have no prior experience with 
mindfulness meditation, and have a BMI of less than 30 kg/m2. All enrolled participants 
met the criteria for inclusion and were in good health. Participants read and completed a 
consent form and were informed they could discontinue the study at any time with no 
penalty. There was no monetary compensation for this study. Due to the COVID-19 
pandemic, data collection was prematurely terminated. Two additional participants 
underwent the orientation session but were not able to return to the lab for the 
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intervention session due to university shutdown; therefore, those data could not be 
included for analysis. 
2.2.2 Orientation session 
During the orientation session, participants were familiarized with the laboratory 
setting, equipment, and informed about the study. Any questions or concerns about the 
study were answered by the primary investigator at this time. 
Participants’ height and weight were measured. A wall-mounted stadiometer was 
used to record height, while weight and body mass index were recorded with a digital 
scale (Tanita BC-418). Body mass index (BMI) was calculated as weight (kg) divided by 
height (m2).  Then, participants were instructed to sit in a chair and quietly relax with 
their legs uncrossed for five minutes to ensure accurate blood pressure measurements. 
Three seated and supine blood pressures were recorded and averaged with an automated 
sphygmomanometer (Omron HEM907-XL) to calibrate the SphygmoCor system. Heart 
rate (HR), pulse wave analysis (PWA), pulse wave velocity (PWV), aortic augmentation 
index (AIx), and aortic augmentation index normalized to 75 heart beats per minute 
(AIx@75), central pulse wave velocity, aortic pulse pressure (aPP), and aortic pulsatile 
load (aPL) were the cardiovascular measurements of interest for this study. All of the 
above variables except for aPL were recorded from the SphygmoCor system. Aortic 
pulsatile load was manually calculated as HR * aPP. 
To begin cardiovascular data collection, participants were instructed to lie down 
in a relaxed supine position with the palm of their right hand supinated. Measurements 
were collected for PWA, AIx, and AIx@75 by placing the SphygmoCor tonometry probe 
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directly on the site of the radial artery and gently pressing down against dense connective 
tissue and the radial carpal bones. Recordings were taken for at least 10 full cardiac 
cycles while maintaining a stationary position with the probe. Acceptable recordings 
required an operator index of 75 or higher on the SphygmoCor software. Duplicate 
recordings were taken and averaged for analysis. 
Central arterial stiffness measurements, otherwise known as carotid femoral pulse 
wave velocity (cfPWV), were recorded using the carotid artery and femoral artery sites. 
These sites were palpated and marked with a marker dot or piece of opaque tape for the 
carotid and femoral sites, respectively. The straight-line distance of each of these sites 
relative to the suprasternal notch were measured and recorded to the closest millimeter. 
Three ECG electrodes were placed on the skin, located under the right and left clavicles 
and on the left anterior and inferior portion of the ribcage to record heart rhythms and R-
waves. These recorded R-waves were gated to carotid or femoral pressure waves to 
calculate the time it takes for a pulse wave to arrive at each specified site after the heart 
begins ejecting blood. PWV is determined simply by the change in distance (in meters) 
divided by the time (in seconds). These measurements were also duplicated and averaged 
for analysis. 
To assess cfPWV with the SphygmoCor system, the straight-line distances and 
average supine blood pressure were entered into the software. Recordings were taken by 
placing the tonometry probe on the marked carotid site for at least 10 cardiac cycles, then 
again on the femoral site. The order was then reversed for another set of recordings. Data 
were deemed acceptable if the two recordings were within 1 m/s of each other and the 
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standard deviation of the PWV for each cardiac cycle between the two recording sites 
was less than 10.0%. These trials were then averaged for analysis. 
Participants then completed the Spielberger State Anxiety Inventory (Form Y). 
The Spielberger State Anxiety Inventory is a 20-item self-reported measure of state 
anxiety, or how an individual feels right now, in this moment. This inventory uses a 
Likert-type scale, ranging from 1 (not at all) to 4 (very much so). Participants were then 
scheduled for the intervention session day which occurred approximately one week later. 
2.2.3 Intervention session 
Upon return to the laboratory for the second session, all blood pressure and 
cardiovascular measurements were repeated in the same way as the orientation session. 
Participants chose to either sit in a chair or lie down for the meditation intervention. 
Before beginning the mindfulness interventions, one overhead light was dimmed for 
relaxation purposes and participants were offered either a pillow for their head (supine) 
or a meditation cushion (seated). 
First, a two-minute introduction to mindfulness meditation video (Meditation 101 
- https://www.youtube.com/watch?v=rqoxYKtEWEc) was viewed. This video informs 
the participant about the benefits of mindfulness and how to practice mindfulness quickly 
and simply each day. Participants then listened to two guided meditations (Mindfulness 
Meditation in 20 Minutes - https://www.youtube.com/watch?v=64ZU2UCQdmQ; Body 
Scan, Palouse Mindfulness - https://palousemindfulness.com/meditations/bodyscan.html) 
for a total duration of 55 minutes. These body scans invited the participant to first focus 
on lengthening the breath. Then, the participants were cued to focus on individual 
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segments of their body and how they feel in that moment with constant attention on the 
breath.  
Following the intervention, participants remained supine or sitting for a one-hour 
rest period. During this time, participants were allowed to read, draw, or listen to music, 
but were not permitted to use electronic devices with screens. At the 55th minute of rest, 
the participant repeated the Spielberger State Anxiety Inventory. Cardiovascular 
measurements were taken post-intervention after the 60th minute of rest. 
2.2.4 Statistical Analysis 
Statistical data analyses were completed by using IBM SPSS Version 20 
(Armonk, NY). Normality was assessed prior to further analysis and assumptions were 
met. Data are expressed as mean ± standard error.  
Repeated measures analysis of variance (ANOVA) were conducted to assess time 
effect changes in all cardiovascular variables at three time intervals: orientation, pre-
intervention, and post-intervention. These variables include SAP, DAP, HR, PP, AIx, 
AIx@75, cfPWV, and aPL. Mauchly’s Test of Sphericity was performed for each 
variable to determine whether sphericity could be assumed. Significance for within-
subject effects for time were concluded assuming sphericity or using Greenhouse-
Geisser. Additionally, post-hoc Bonferroni pairwise comparisons and paired t-tests were 
performed for any significant ANOVA data. Data were considered significantly different 
when p<0.05. 
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2.3 Results 
Orientation, pre-intervention, and post-intervention variables (Table 1) were 
analyzed to ensure there were no differences in baselines between the two testing days. 
There were no significant differences between any orientation and pre-intervention 
measurements.  
Table 1. Cardiovascular and anxiety variables comparing orientation, pre-intervention, 
and post-intervention measurements. Values are considered significant when P < 0.05. 
Variable Orientation Pre-Intervention Post-Intervention P-value
SAP (mmHg) 111 ± 4 109 ± 4 109 ± 3 0.696 
DAP (mmHg) 61 ± 2 62 ± 2 63 ± 2 0.527 
HR (bpm) 62 ± 3 62 ± 3 58 ± 2 0.060 
AIx -4.6 ± 3 -3.6 ± 3 -4.5 ± 3 0.920 
AIx @ 75 -8.4 ± 3 -11.5 ± 2 -13.0 ± 4 0.194 
cfPWV (m/s) 4.8 ± 0.2 5.1 ± 0.2 4.9 ± 0.1 0.323 
aPP (mmHg) 30 ± 2 29 ± 2 27 ± 1 0.157 
aPL (mmHg) 1811 ± 138 1785 ± 127 1555 ± 113 0.037 
State anxiety 35 ± 4 34 ± 4 32 ± 5 0.350 
Values are reported as mean ± SE. Systolic arterial pressure (SAP), diastolic arterial 
pressure (DAP), heart rate (HR), aortic augmentation index (AIx), aortic augmentation 
index normalized to 75 heart beats per minute (AIx@75), carotid-femoral pulse wave 
velocity (cfPWV), aortic pulse pressure (aPP), and aortic pulsatile load (aPL). 
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There was a significant time effect for changes in aPL. Aortic pulsatile load 
remained relatively the same between orientation and pre-intervention sessions but 
decreased significantly after the meditation intervention as depicted in Figure 3. A post-
hoc paired samples t-test was performed for aortic pulsatile load data due to its previous 
significance from the ANOVA test.  
 
  
 
There were no significant differences between time points for other 
cardiovascular variables or for the state anxiety inventory. Aortic pulse pressure (Figure 
5a) was unchanged between all time points. HR demonstrated a downward trend but was 
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Figure 3. Time effect changes in aortic pulsatile load (aPL) at three time points. Data are 
significant when P < 0.05. *Difference from pre-intervention to post-intervention time 
points. 
P = 0.018 
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not significant. SAP remained relatively constant, as well as DAP, AIx, AIx@75, and 
cfPWV. Last, there was no change in state anxiety from the state anxiety inventory. 
  
26
27
28
29
30
31
32
O Pre Post
aP
P 
(m
m
H
g)
56
58
60
62
64
66
O Pre Post
H
R
 (b
pm
)
Figure 4a and 4b. Time-effect changes in (a) aortic pulse pressure (aPP) and (b) heart rate 
(HR) at three time points. Data are significant when P < 0.05.  
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2.4 Discussion 
The major finding of this study indicates there is a significant decrease in aPL 
after a one-hour acute meditation intervention. This suggests that even short periods of 
mindfulness meditation can provide cardiovascular benefits to those who practice it. 
These results are consistent with a previous study in which mild to moderately anxious 
adults saw improvements in aPL after an hour long mindfulness meditation intervention 
(19).   
Aortic pulsatile load is calculated by multiplying heart rate by pulse pressure. 
This value provides a good estimate of the mechanical stress placed on the proximal 
aorta, heart, and other organs such as the brain and kidneys. Increased pulsatile load can 
lead to cardiovascular dysfunction such as left ventricle remodeling and hypertrophy, 
which can lead to heart failure and death (3, 73). As pressure in the aorta increases, 
afterload increases, thus forcing the heart to have to eject blood with more force to 
overcome the pressure of blood within the aorta. The repeated, pulsatile mechanical stress 
of the blood against the proximal aorta can damage elastin fibers found in the arteries 
(32). As these fibers are damaged and replaced with stiffer, collagen fibers (10), their 
ability to expand and slowly recoil to accommodate the pulsatile flow of blood from the 
left ventricle diminishes.  
Additionally, aPP, HR, AIx, AIx@75, and cfPWV were relatively unchanged. 
Because both aPP and HR decreased between pre-intervention and post-intervention, aPL 
was significantly reduced.  Previous studies have demonstrated that pulse pressure is a 
better estimate than systolic blood pressure in regard to cardiovascular risk factors, as it 
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more closely represents the stress placed on the left ventricle and coronary arteries (60). 
Mechanistically, these reductions may also be partially due to a diminished stress 
response from the hypothalamic-pituitary-adrenal (HPA) axis due to a state of general 
relaxation.  
Our study did not find any significant decreases in SAP or DAP before and after 
meditation. This is consistent with previous literature in which no blood pressure changes 
were detected in normotensive meditators after one hour of meditation (66). This could 
be due to the already normal or lower blood pressure levels in our participants. However, 
previous studies have found significant decreases in blood pressure after longitudinal 8-
week mindfulness based stress reduction programs (29, 57) as well as transcendental 
meditation in hypertensive individuals (50). An acute meditation session may improve 
blood pressure better in hypertensive individuals but further research with this criterion 
should be completed.  
While a variety of other acute studies have demonstrated significant decreases in 
anxiety or other negative emotions after meditation (16, 19, 50), we found that state 
anxiety remained unchanged from pre-intervention to 60 minutes post-intervention. We 
hypothesized there would be a larger, more significant difference in stress between pre-
intervention and post-intervention. This discrepancy could be due to the waiting period 
between the end of meditation and the recording of cardiovascular variables 60 minutes 
later. Because our participants were inexperienced meditators, this relaxed state may not 
have carried over for the duration of the rest period. 
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Online guided mindfulness practices and courses can be used to further increase 
the accessibility of mindfulness meditation. Cavanagh, et al., concluded that an online-
based, shortened program of two weeks found similar pre-test to post-test results, 
including significant increases in mindfulness and reductions in depression and anxiety 
symptoms, compared to a wait-listed control group (11). However, further studies should 
be completed comparing an online meditation cohort to an in-person cohort to determine 
the efficacy of this mindfulness medium. The potential availability of an online program 
can improve the availability of mindfulness meditation interventions platform to reach a 
wider variety of people. 
In conclusion, short bouts of mindfulness meditation may be an effective way to 
decrease pulsatile load in the aorta. Acute meditation sessions may also decrease heart 
rate as well, but further investigation should be done with a larger sample size. Along 
with hypertension, CVDs have other attributable risk factors including arterial stiffness 
and pulsatility; thus, the addition of mindfulness meditation practices into daily routine 
may target other factors that antihypertensive drugs do not (55).
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3. Study 2: Decentering and Arterial Stiffness
3.1 Introduction 
The stiffness of large, central arteries in the body can be an important predictor of 
cardiovascular morbidity and mortality (69). Specifically, carotid-femoral pulse wave 
velocity (cfPWV) is a robust, accurate, and independent predictor of aortic stiffness and 
cardiovascular events (70). It can be assessed noninvasively with relative ease and is 
considered the gold standard method of measuring arterial stiffness (10). Overactivation 
of the stress pathway via psychological or psychosocial trauma can increase arterial 
stiffness prematurely (9). This can lead to adverse cardiovascular events at a younger age. 
Mindfulness meditation is an ancient practice used to combat stress for centuries. 
While it has roots in Buddhist tradition, mindfulness meditation practices today are non-
secular and inclusive. An important subcategory of mindfulness is decentering. 
Decentering is the ability to dissociate oneself from thoughts and emotions and accept a 
distant perspective (26). This mindset serves those practicing mindfulness as it combats 
rumination of negative thoughts by accepting them as transient, rather than permanent 
associations of oneself. The ability to decenter has been associated with an increased 
tolerance, or acceptance, of chronic pain as well as improvements in depressive 
symptoms and anxiety (22-24, 44). 
While previous research on decentering has studied the psychological benefits, 
little is known about its relationship to cardiovascular physiology and specifically arterial 
stiffness. Therefore, the purpose of this study is to investigate the relationship between 
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the ability to decenter and arterial stiffness in individuals without previous meditation 
training. Previous studies have found that improvements in an individual’s ability to 
decenter were associated with decreases in anxiety in individuals with generalized 
anxiety disorder (GAD) (26). Further, anxiety was robustly correlated with hypertension 
(29, 39, 40) and reductions in anxiety and stress were linked to positive cardiovascular 
outcomes such as decreases in blood pressure (56). Thus, we hypothesized that 
individuals who had a better ability to decenter would have lower arterial stiffness 
compared to those who had a lesser ability to decenter. 
3.2 Methods 
All testing took place in the Clinical and Applied Human Physiology Laboratory 
in the Biological Sciences department or in the Sleep Research Laboratory in the 
Kinesiology and Integrative Physiology department at Michigan Technological 
University. All protocols were approved by the Michigan Tech Institutional Review 
Board and all participants volunteered their written informed consent prior to any testing. 
3.2.1 Subjects 
A random sample of participants was recruited via flyers, email, and word of 
mouth. Fifty-five (55) healthy individuals enrolled in this study, with an average age of 
24 ± 1 years old, and an average BMI of 24 ± 3 kg/m2. One participant’s data was 
omitted from final analyses due to the failure to complete the Experiences Questionnaire 
(EQ), thus data were collected for fifty four (54) participants.  
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36 males (24 ± 1 years old) and 18 females (23 ± 1 years old) completed the 
study. Participants were excluded from the study if they had previous experience with 
mindfulness meditation, defined as participating in a formal mindfulness meditation or 
mindfulness-based stress reduction (MBSR) course in the past. Additional exclusion 
criteria included smoking or vaping, taking cardiovascular or blood pressure medication, 
diabetes, or pregnancy. Participants volunteered to partake in this study and were 
informed they could withdraw at any point. There was no monetary compensation for 
completion of this study. 
3.2.2 Experimental protocol 
 Participants were instructed to meet in the laboratory the day of testing having 
abstained from alcohol and caffeine consumption and exercise for at least twelve (12) 
hours prior to testing. Additionally, subjects were instructed to abstain from eating for at 
least three hours before measurements were recorded. Upon arrival, the investigator 
verbally explained the testing procedures and answered any questions volunteers had, and 
consent and exclusion criteria forms were completed. Participants also completed the 11-
item Decentering Questionnaire (Experiences Questionnaire, EQ). This questionnaire 
measures an individual’s current ability to decenter by gauging their ability to distance 
themselves from their thoughts, demonstrate self-compassion, and avoid habitual 
reactivity (i.e., rumination) to negative stimuli (22).  
 Subjects’ heights were recorded using a wall-mounted stadiometer. Weight and 
body mass index (BMI) were recorded using an impedance analysis of body fat scale 
(Tanita BC-418). Then, participants were instructed to sit quietly and comfortably in a 
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chair for five minutes to achieve a relaxed, rested state. Three seated blood pressure 
recordings were measured and averaged using an automated sphygmomanometer (Omron 
HEM-907XL).  
Triplicate supine recordings were measured and averaged following an additional 
five-minute rest period to calibrate the applanation tonometry system (SphygmoCor). 
Pulse wave analysis (PWA) at the radial artery site was performed in duplicate recordings 
to determine aortic augmentation index (AIx) and AIx normalized to 75 heart beats per 
minute (AIx @75). These values were averaged. 
To measure heart rate and gate central and peripheral pulse waves, an 
electrocardiogram (ECG) was performed, attached to participants via three skin 
electrodes. cfPWV and peripheral (femoral artery to carotid artery) pulse wave velocity 
was performed to assess arterial stiffness at regional sites.  
3.2.4 Statistical Analysis 
Statistical data analyses were done using IBM SPSS Version 20 (Armonk, NY). 
Normality was assessed prior to further analysis. A median analysis was performed to 
compare arterial stiffness values in individuals with a high versus low ability to decenter. 
Independent samples t-tests were conducted to compare the two groups. Pearson 
correlations were performed to determine any associations between the independent 
variable (decentering) and dependent variables (AIx, AIx@75, cfPWV). Differences 
were considered significant if P-values were <0.05. Data are expressed as mean ± 
standard error. 
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3.3 Results 
A median analysis was performed to categorize participants into either the “low 
decentering” (n=27) or “high decentering” (n=27) group. The high decentering group was 
composed of 10 females and 17 males, while the low decentering group contained 8 
females and 19 males. The median score was 40, with the low decentering group scoring 
in the range of 26-39 on the Experiences Questionnaire (range of possible scores = 11 to 
55) and the high decentering group scoring from 40-54.  
Baseline anthropometrics and cardiovascular data are presented in Table 2 as the 
mean ± standard deviation. There were no significant differences in any anthropometric 
or cardiovascular data between participants in the low decentering group compared to the 
high decentering group, suggesting that any differences between the groups are not 
related to these variables. 
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Table 2. Participant anthropometrics and seated resting cardiovascular variables. Values 
are significant when P < 0.05. 
Variable 
Low decentering 
(n = 27; 24 ± 5 
years) 
High decentering 
(n=27; 23± 5 
years) 
P value 
Height (cm) 172 ± 2 173 ± 2 0.731 
Weight (kg) 74 ± 3 72 ± 3 0.559 
BMI (kg/m2) 25 ± 1 24 ± 1 0.237 
SAP (mmHg) 122 ± 2 119 ± 3 0.340 
DAP (mmHg) 74 ± 2 69 ± 2 0.090 
MAP (mmHg) 90 ± 2 86 ± 2 0.156 
HR (bpm) 67 ± 2 71 ± 2 0.186 
Values are mean ± SE. Body mass index (BMI), systolic arterial pressure (SAP), diastolic 
arterial pressure (DAP), mean arterial pressure (MAP), and heart rate (HR). 
AIx and AIx@75 were similar in the high decentering group compared to the low 
decentering group, but this difference was not significant (Table 3). cfPWV was 
significantly lower in individuals who were better able to decenter than those who had a 
poor ability to decenter (5.6 ± 0.1 m/s vs. 5.1 ± 0.1 m/s, P = 0.012) as depicted in Figure 
6.
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Table 3. Median analysis of cardiovascular variables. Data are significant when P < 0.05. 
Variable Low decentering (n = 27) 
High decentering 
(n = 27) P value 
AIx 4.7 ± 3 0.8 ± 2 0.319 
AIx@75 -2.0 ± 3 -3.0 ± 3 0.780 
 
Values are mean ± SE. Aortic augmentation index (AIx), aortic augmentation index 
normalized to 75 heart beats per minute (AIx@75), and carotid-femoral pulse wave 
velocity (cfPWV). 
 
 
 
Figure 5. Carotid-femoral pulse wave velocity (cfPWV) as a function of a low versus 
high ability to decenter. Individuals in the high decentering group had a significant 
decrease in cfPWV compared to individuals in the low decentering group. *Data are 
significant when P < 0.05. 
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Decentering was also weakly correlated (r = -0.349, P = 0.01) with cfPWV as 
depicted in Figure 7. Both AIx and AIx@75 were not significantly correlated with 
decentering (AIx: r = -0.145, p=0.296; AIx@75: r = -0.066, P = 0.638). 
Figure 6. Correlational data for cfPWV and decentering. Higher decentering scores are 
correlated with slower central pulse wave velocity. Data are significant when P < 0.05. 
3.4 Discussion 
To our knowledge, this is the first study to report the relationship between an 
individual’s ability to decenter and pulse wave velocity. Individuals who scored higher 
on the Experiences Questionnaire demonstrated a greater ability to decenter. This is 
inversely correlated with cfPWV, suggesting that a greater ability to decenter is 
significantly associated with a lower pulse wave velocity. Individuals in the high 
decentering group had a 0.5 m/s slower cfPWV than those in the low decentering group. 
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The significant reduction in cfPWV between the high decentering and low 
decentering groups suggests that developing this component of mindfulness may not only 
benefit people psychologically, but through cardiovascular health as well. The stiffening 
and lengthening of large central arteries are a normal process of aging (12). However, this 
process can be accelerated at a premature age due to a variety of factors, including 
hypertension, obesity, and excess stress (10). While some lifestyle changes, such as 
improving diet and increasing physical activity can help mitigate these, chronic stress can 
be more challenging to cope with. Individuals who are more chronically stressed may 
suffer from overstimulation of the sympathetic nervous system and the hypothalamic-
pituitary-adrenal (HPA) axis. Among other functions, the HPA axis modulates the release 
of the stress hormone cortisol, which is essential for the stress response (8). However, 
issues arise when cortisol release becomes prolonged and chronic. This can cause 
inflammation, damage to the endothelium of the vessels, and smooth muscle hyperplasia, 
all of which contribute to increasing blood pressure and arterial stiffness (7, 22).    
While this study measured an individual’s unpracticed, inherent ability to 
decenter, decentering scores can be improved. Previous research has shown that an 8-
week mindfulness-based stress reduction (MBSR) course improves people’s ability to 
decenter (26). Decentering provides a positive coping mechanism for individuals who 
may be stressed or anxious. One study found that individuals who used task-oriented 
coping (focusing on the solution to a problem) were significantly less likely to have or 
develop hypertension than those who implemented emotional-oriented coping 
(ruminating on feelings) (19). This suggests that shifting coping mechanisms and 
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eliminating rumination on negative feelings and emotions are related to improvements in 
cardiovascular health. This is comparable to improving decentering.  
 In conclusion, the ability to decenter has important implications for 
cardiovascular health. Those who are better able to separate themselves from their 
thoughts and emotions tend to have more elastic arteries and a slower cfPWV. These 
results are relevant as previous studies with large sample sizes indicate that even a 1 m/s 
reduction in cfPWV may reduce the risk of cardiovascular events by 10% (70).  This 
novel finding can offer new insight into the complicated relationship between the mind 
and body. It also strengthens the argument for the implementation of more MBSR-type 
courses into clinical settings in conjuncture with other lifestyle modifications.  
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4. Summary, Limitations, and Future Directions 
4.1 Summary 
 Our results suggest that even an acute session of mindfulness meditation can have 
positive effects on the cardiovascular system. Additionally, individuals who are more 
mindful via decentering have slower pulse wave velocities. These novel findings 
advocate for the implementation of mindfulness interventions into daily life for 
improvements in cardiovascular health and wellbeing. 
4.2 Limitations 
While this research provides novel insights and considerations for mindfulness 
meditation and cardiovascular health, there are some limitations associated with the 
studies. First, due to the small number of participants of Study 1, there was no control 
group; however, the baseline data was comparable to the pre-mindfulness intervention, 
suggesting that any changes observed were in fact due to the meditation intervention. The 
small cohort also limits our ability to study possible sex differences in how they respond 
to a mindfulness intervention. The absence of a follow-up after the acute intervention is 
also a limitation. Having data on the longitudinal effects of a single session of 
mindfulness meditation would be insightful. Last, a lack of counterbalance in the order of 
measurements (i.e., providing the state anxiety questionnaire before versus after arterial 
stiffness measurements) may have provided a less accurate measure of state anxiety. 
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The use of seated, clinical blood pressure recordings may have impacted results. 
Ambulatory blood pressure monitoring is a more accurate representation of blood 
pressure on a day-to-day scale as it may fluctuate throughout a normal day due to 
everyday stressors as opposed to the controlled laboratory setting (42). To minimize this 
limitation, we took triplicate BP recordings after a standardized resting period at a similar 
time of day for between the two meetings. 
Additionally, both studies enrolled primarily college-aged, healthy participants. 
This limits the scope of our studies in determining if mindfulness would be beneficial in 
older individuals who are more prone to arterial stiffness due to more advanced age.  
4.3 Future Directions 
Since physiology-focused mindfulness meditation research is still in its infancy, 
there are a variety of directions that this research can expand upon in the future. For acute 
meditation and continuing with previous research by Durocher, et al., a future 
consideration could be comparing the reliability of the BAI and STAI in individuals 
undergoing mindfulness interventions (19). Future studies should also include an in-
person, instructor-led meditation cohort as a control to compare to an online recorded 
audio format. More invasive procedures could be implemented as well, including salivary 
and serum cortisol to gain insight on sympathetic and HPA axis response, or blood lipid 
levels. Additional routes with mindfulness research include studying the effects of acute 
mindfulness on sleep patterns. This could include cardiovascular variables throughout 
sleep such as blood pressure dipping.   
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Appendix A: Raw Data for Study 1 
A.1 Demographic Information
SUBJECT # SEX 
AGE 
(years) 
HEIGHT 
(cm) 
WEIGHT 
(kg) 
BMI 
(kg/m2) 
1 F 19 160 65 25.2 
2 M 18 173 52 17.5 
3 F 28 152 35 15.2 
4 M 23 185 90 26.2 
5 F 23 162 65 24.7 
6 M 19 173 63 21.1 
7 F 19 178 70 22.1 
8 M 21 173 72 24.1 
9 F 22 163 59 22.2 
10 F 19 163 47 17.7 
11 M 19 180 93 28.7 
12 F 20 173 62 20.7 
13 F 26 170 63 21.8 
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A.2 Brachial Hemodynamics: Orientation 
Subject # 
SAP  
(mmHg) 
DAP 
(mmHg) 
MAP  
(mmHg) 
HR  
(bpm) 
1 97 50 66 59 
2 100 60 73 76 
3 94 55 68 43 
4 117 63 81 50 
5 132 74 93 58 
6 128 60 83 77 
7 116 59 78 69 
8 128 64 85 71 
9 99 58 72 59 
10 98 50 66 56 
11 124 72 89 72 
12 123 68 86 68 
13 84 58 67 63 
A.3 Aortic Hemodynamics – Trial 1: Orientation 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 77 50 61 27 68 
2 83 61 71 22 70 
3 84 55 68 29 41 
4 96 63 77 33 48 
5 107 75 90 32 54 
6 100 62 78 38 70 
7 93 59 72 34 64 
8 102 64 81 38 63 
9 85 59 71 26 58 
10 79 50 63 29 52 
11 102 73 87 29 67 
12 100 69 82 31 66 
13 74 58 66 16 60 
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A.4 Aortic Hemodynamics – Trial 2: Orientation 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 77 50 62 27 75 
2 83 61 71 22 75 
3 83 55 67 28 41 
4 97 64 78 33 49 
5 107 75 91 32 58 
6 100 62 77 38 74 
7 94 59 73 35 69 
8 102 65 83 37 65 
9 85 59 72 26 54 
10 79 50 64 29 54 
11 102 73 86 29 72 
12 100 69 83 31 67 
13 75 59 67 16 60 
A.5 Pulse Wave Analysis: Orientation 
   Trial 1            Trial 2 
Subject # AIx AIx @ 75 AIx AIx @ 75 
1 -23 -26 -20 -21 
2 -19 -21 -19 -18 
3 21 5 19 3 
4 -10 -23 -9 -22 
5 -5 -15 -5 -13 
6 -5 -8 -14 -15 
7 -6 -11 -15 -18 
8 -3 -8 -2 -7 
9 12 2 11 1 
10 -6 -17 1 -7 
11 -7 -11 -11 -12 
12 -10 -15 -9 -13 
13 8 1 14 7 
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A.6 Pulse Wave Velocity: Orientation 
 Trial 1 Trial 2 
Subject  
Velocity  
(m/s) SD 
Velocity 
(m/s) SD 
1 4.3 0.3 4.2 0.3 
2 5.7 0.4 6 0.5 
3 4.9 0.5 4 0.2 
4 4.7 0.2 4.2 0.3 
5 5.5 0.3 5.7 0.3 
6 4.4 0.4 5.1 0.4 
7 4.4 0.2 3.9 0.2 
8 4.9 0.3 5.1 0.4 
9 5.3 0.2 5 0.2 
10 3 0.2 3.4 0.2 
11 6.5 0.6 5.3 0.5 
12 6 0.4 5.8 0.6 
13 4.4 0.3 4 0.2 
A.7 Brachial Hemodynamics: Pre-Intervention 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
HR  
(bpm) 
1 97 51 66.3 62 
2 102 62 75.3 69 
3 93 54 67 35 
4 117 63 81 50 
5 111 72 85 58 
6 115 63 80.3 74 
7 119 61 80.3 68 
8 129 75 93 67 
9 99 56 70.3 71 
10 131 69 89.7 72 
11 120 63 82 67 
12 89 62 71 71 
13 111 62 78.3 66 
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A.8 Aortic Hemodynamics – Trial 1: Pre-Intervention 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 77 51 62 26 57 
2 87 63 73 24 65 
3 90 54 68 36 39 
4 88 57 70 31 49 
5 95 73 85 22 56 
6 93 64 78 29 72 
7 96 62 78 34 72 
8 102 65 81 37 62 
9 90 62 74 28 59 
10 81 57 67 24 66 
11 106 70 87 36 69 
12 98 64 79 34 61 
13 77 62 69 15 71 
A.9 Aortic Hemodynamics – Trial 2: Pre-Intervention 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 77 51 63 26 60 
2 87 63 74 24 67 
3 90 55 70 35 39 
4 88 57 71 31 53 
5 96 73 85 23 58 
6 94 63 76 31 67 
7 96 62 76 34 65 
8 103 65 84 38 69 
9 90 62 75 28 65 
10 82 57 69 25 67 
11 105 70 86 35 72 
12 97 64 79 33 61 
13 77 62 70 15 72 
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A.10 Pulse Wave Analysis: Pre-Intervention 
 Trial 1         Trial 2 
Subject # AIx AIx @ 75 AIx AIx @ 75 
1 -12 -19 -11 -20 
2 -7 -10 -5 -10 
3 34 - 34 - 
4 -15 -26 -17 -30 
5 4 -5 -1 -10 
6 -9 -13 -6 -7 
7 -3 -8 -2 -4 
8 2 -1 -4 -10 
9 -12 -17 -9 -17 
10 -7 -10 -6 -11 
11 -16 -18 -18 -21 
12 1 -6 -4 -11 
13 -5 -6 -2 -4 
 
A.11 Pulse Wave Velocity: Pre-Intervention 
 Trial 1 Trial 2 
Subject #  
Velocity  
(m/s) SD 
Velocity 
(m/s) SD 
1 3.9 0.3 4.6 0.3 
2 4.5 0.3 5 0.3 
3 5.8 0.4 6.6 0.3 
4 4.5 0.3 5.5 0.4 
5 5.5 0.5 5.7 0.6 
6 4.7 0.3 5.1 0.4 
7 5.1 0.4 4.2 0.3 
8 5.7 0.4 6 0.3 
9 5.2 0.3 4.8 0.3 
10 3.3 0.3 4.2 0.2 
11 5.6 0.3 5.6 0.3 
12 5.2 0.4 5.7 0.5 
13 5.3 0.5 5.7 0.5 
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A.12 Brachial Hemodynamics: Post-Intervention 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
HR  
(bpm) 
1 99 54 69 63 
2 95 58 70 53 
3 93 54 67 46 
4 111 61 78 44 
5 115 80 92 49 
6 104 57 73 59 
7 118 57 77 71 
8 117 62 80 56 
9 111 64 80 62 
10 96 57 70 59 
11 122 65 84 65 
12 119 71 87 80 
13 111 73 86 64 
 
A.13 Aortic Hemodynamics – Trial 1: Post-Intervention 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 80 54 65 26 60 
2 79 58 68 21 53 
3 83 55 68 28 51 
4 90 61 73 29 44 
5 101 80 90 21 48 
6 84 57 68 27 58 
7 93 58 75 35 70 
8 94 63 76 31 56 
9 91 65 77 26 62 
10 79 58 67 21 56 
11 99 66 83 33 67 
12 94 65 78 29 55 
13 100 77 88 23 63 
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A.14 Aortic Hemodynamics – Trial 2: Post-Intervention
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 79 54 63 25 65 
2 79 58 67 21 53 
3 84 55 67 29 41 
4 90 61 72 29 43 
5 101 81 91 20 50 
6 84 57 70 27 60 
7 92 57 73 35 72 
8 94 63 76 31 56 
9 91 65 77 26 61 
10 79 57 67 22 61 
11 99 66 82 33 63 
12 94 65 78 29 58 
13 100 77 88 23 65 
A.15 Pulse Wave Analysis: Post-Intervention
Trial 1   Trial 2 
Subject # AIx AIx @ 75 AIx AIx @ 75 
1 -19 -26 -19 -24
2 -15 -26 -12 -23
3 18 7 21 5
4 -17 -32 -24 -39
5 7 -6 7 -5
6 -10 -18 -5 -13
7 -4 -7 -8 -9
8 -6 -16 -6 -15
9 -13 -19 -7 -14
10 -10 -19 -11 -18
11 1 -3 2 -4
12 -11 -21 -9 -17
13 17 11 16 11
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A.16 Pulse Wave Velocity: Post-Intervention
Trial 1 Trial 2 
Subject # 
Velocity 
(m/s) SD 
Velocity 
(m/s) SD 
1 5 0.4 5 0.5 
2 4.2 0.2 4.8 0.1 
3 4.7 0.3 5.2 0.1 
4 4.4 0.3 4.9 0.5 
5 5.3 0.3 4.9 0.2 
6 4.9 0.3 4.6 0.5 
7 4.1 0.2 4.8 0.3 
8 5.3 0.4 5.7 0.5 
9 5.3 0.3 6 0.8 
10 4.3 0.2 4 0.2 
11 5.7 0.4 5.3 0.2 
12 5.1 0.3 4.8 0.2 
13 5.2 0.3 4.6 0.3 
A.17 Questionnaires: Orientation
Subject # Resilience State 
1 157 20 
2 159 27 
3 - 54
4 168 20
5 145 41
6 144 24
7 107 34
8 122 59
9 167 49
10 150 29
11 133 46
12 166 25
13 156 26
 
57 
 
A.18 Questionnaires: Pre-Intervention  
Subject # Decentering State Trait Mindfulness 
1 46 20 28 141 
2 53 27 36 136 
3 33 54 54 117 
4 46 26 25 165 
5 40 27 38 112 
6 - 24 37 139 
7 26 30 54 116 
8 26 55 62 97 
9 51 34 36 113 
10 48 34 27 153 
11 35 66 62 136 
12 48 25 25 162 
13 40 25 32 133 
A.19 Questionnaires: Post-Intervention 
Subject # State 
1 20 
2 21 
3 57 
4 20 
5 26 
6 22 
7 33 
8 52 
9 21 
10 22 
11 69 
12 20 
13 27 
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Appendix B: Summary Statistics for Study 1 
B.1 Aortic Pulsatile Load
Repeated Measures ANOVA 
Mauchly's Test of Sphericity  
Within Subjects 
Effect Mauchly's W 
Approx. 
Chi-Square df Sig. Greenhouse-Geisser 
Time 0.670 4.401 2 0.111 0.752 
Tests of Within-Subjects Effects  
Source 
Type III 
Sum of Squares df Mean Square F 
Partial 
Eta 
Squared Sig. 
Time Sphericity Assumed 518786.369 2 259393.184 3.788 0.222 0.037 
Greenhouse-Geisser 518786.369 1.504 344928.598 3.788 0.222 0.053 
Huynh-Feldt 518786.369 1.672 310221.068 3.788 0.222 0.047 
Lower-bound 518786.369 1.000 518786.369 3.788 0.222 0.075 
Pairwise Comparisons (Bonferroni) 
95% Confidence 
Interval 
(I) Time
(J) 
Time 
Mean 
difference (I-
J) SE Sig 
Lower 
Bound 
Upper 
Bound 
1 (O) 2 (Pre) 26.115 88.833 0.774 -167.44 219.666 
2 (Pre) 3 (Post) 230.558 84.52 0.018 46.404 414.711 
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Post Hoc Paired T-Tests 
95% Confidence Interval  
Mean 
Std. 
Deviation Lower Upper T df 
Sig. (2-
tailed) 
O aPL - Pre aPL 26.11538 320.29245 167.43541 219.66618 0.294 12 0.774 
Pre aPL - Post aPL 230.55769 304.74206 46.40391 414.71147 2.728 12 0.018 
B.2 Aortic Pulse Pressure
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. 
Chi-Square df Sig. 
Greenhouse-
Geisser 
Time 0.866 1.589 2 0.452 0.881 
Tests of Within-Subjects Effects  
Source 
Type III  
Sum of Squares df Mean Square F 
Partial 
Eta 
Squared Sig 
Time Sphericity Assumed 48.667 2 24.333 2.190 0.154 0.134 
Greenhouse-Geisser 48.667 1.763 27.606 2.190 0.154 0.141 
Huynh-Feldt 48.667 2.000 24.333 2.190 0.154 0.134 
Lower-bound 48.667 1.000 48.667 2.190 0.154 0.165 
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B.3 Heart Rate
Mauchly's Test of Sphericity  
Within Subjects
Effect 
Mauchly's 
W 
Approx. 
Chi-Square df Sig. 
Greenhouse-
Geisser 
Time 0.886 1.336 2 0.513 0.897 
Tests of Within-Subjects Effects  
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 170.462 2 85.231 3.172 0.166 0.060 
Greenhouse-Geisser 170.462 1.795 94.976 3.172 0.166 0.067 
Huynh-Feldt 170.462 2.000 85.231 3.172 0.166 0.060 
Lower-bound 170.462 1.000 170.462 3.172 0.166 0.100 
B.4 Systolic Arterial Pressure
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.68 4.239 2 0.120 0.758 
Tests of Within-Subjects Effects  
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 36.974 2 18.487 0.368 0.030 0.696 
Greenhouse-Geisser 36.974 1.515 24.399 0.368 0.030 0.640 
Huynh-Feldt 36.974 1.688 21.902 0.368 0.030 0.662 
Lower-bound 36.974 1.000 36.974 0.368 0.030 0.556 
B.5 Diastolic Arterial Pressure
Mauchly's Test of Sphericity  
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Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.875 1.463 2 0.481 0.889 
 
Tests of Within Subjects Effects 
 
Source  
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 19.897 2 9.949 0.658 0.052 0.527 
 Greenhouse-Geisser 19.897 1.779 11.188 0.658 0.052 0.511 
 Huynh-Feldt 19.897 2.000 9.949 0.658 0.052 0.527 
 Lower-bound 19.897 1.000 19.897 0.658 0.052 0.433 
 
B.6 Aortic Augmentation Index 
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.951 0.548 2 0.760 0.954 
 
Tests of Within Subjects Effects 
Source  
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 7.782 2 3.891 0.084 0.007 0.920 
 Greenhouse-Geisser 7.782 1.907 4.080 0.084 0.007 0.912 
 Huynh-Feldt 7.782 2.000 3.891 0.084 0.007 0.920 
 Lower-bound 7.782 1.000 7.782 0.084 0.007 0.777 
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B.7 Aortic Augmentation Index @ 75 BPM
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.998 0.024 2 0.988 0.988 
Tests of Within Subjects Effects 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 146.167 2 73.083 1.755 0.128 0.194 
Greenhouse-Geisser 146.167 1.996 73.245 1.755 0.128 0.195 
Huynh-Feldt 146.167 2.000 73.083 1.755 0.128 0.194 
Lower-bound 146.167 1.000 146.167 1.755 0.128 0.210 
B.8 Carotid-Femoral Pulse Wave Velocity
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.863 1.619 2 0.445 0.880 
Tests of Within Subjects Effects 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 0.532 2 0.266 1.183 0.090 0.323 
Greenhouse-Geisser 0.532 1.759 0.303 1.183 0.090 0.320 
Huynh-Feldt 0.532 2.000 0.266 1.183 0.090 0.323 
Lower-bound 0.532 1.000 0.532 1.183 0.090 0.298 
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B.9 State Anxiety Inventory
Mauchly's Test of Sphericity  
Within Subjects 
Effect 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
Greenhouse-
Geisser 
Time 0.445 8.903 2 0.012 0.643 
Tests of Within Subjects Effects 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F 
Partial Eta 
Squared Sig 
Time Sphericity Assumed 86.000 2 43.000 1.096 0.084 0.350 
Greenhouse-Geisser 86.000 1.286 66.859 1.096 0.084 0.330 
Huynh-Feldt 86.000 1.374 62.587 1.096 0.084 0.333 
Lower-bound 86.000 1.000 86.000 1.096 0.084 0.316 
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Appendix C: Raw Data for Study 2 
C.1 Demographics 
SUBJECT # SEX 
AGE 
(years) 
HEIGHT  
(cm) 
WEIGHT  
(kg) 
BMI 
(kg/m2) 
1 F 42 172 79.5 27.0 
2 M 25 180 94.3 29.1 
3 M 45 168 81.6 29.1 
4 M 20 183 92.1 27.5 
5 M 23 191 86.2 23.8 
6 M 22 186 101.1 29.4 
7 F 27 170 85.5 29.6 
8 M 21 180 84.8 26.2 
9 M 22 180 85.7 26.5 
10 F 19 165 57.6 21.2 
11 F 19 160 64.5 25.20 
12 M 18 173 52.3 17.53 
13 F 19 157 68.9 27.95 
14 M 30 175 72.1 23.54 
15 M 24 193 102.9 27.62 
16 M 20 183 94.8 28.31 
17 M 20 180 67.1 20.71 
18 M 25 172 76.2 25.76 
19 M 21 170 71.2 24.64 
20 F 21 157 58.1 23.57 
21 M 24 175 81.2 26.51 
22 M 23 167 68.0 24.38 
23 M 20 170 58.1 20.10 
24 F 19 170 63.0 21.8 
25 F 28 152 34.9 15.15 
26 M 23 185 89.8 26.24 
27 F 23 162 64.9 24.73 
28 F 19 178 69.9 22.09 
29 M 21 178 66.2 20.83 
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30 M 26 175 73.4 23.04 
31 M 26 157 58 23.53 
32 M 27 186 87 25.15 
33 M 21 171 78 26.67 
34 M 23 185 93 27.17 
35 M 26 175 81 26.45 
36 F 23 155 70 29.14 
37 M 22 178 80 25.25 
38 M 27 183 74 22.10 
39 M 22 167 68 24.38 
40 M 25 168 60 21.26 
41 M 21 189 104 29.11 
42 M 23 159 67 26.50 
43 M 28 175 67 21.88 
44 M 28 177 70 22.34 
45 M 23 162 60 22.86 
46 F 23 170 58 20.07 
47 F 28 148 69 29.86 
48 F 18 152 59 25.54 
49 M 21 178 80 25.25 
50 F 19 163 47 17.69 
51 M 19 180 94.8 29.26 
52 F 20 173 62 20.72 
53 F 26 170 63 21.80 
54 F 22 163 59 22.21 
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C.2 Brachial Hemodynamics 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
HR  
(bpm) 
1 122 81 95 61 
2 125 66 86 67 
3 108 63 78 42 
4 115 56 76 73 
5 137 69 92 66 
6 129 63 85 57 
7 111 67 82 62 
8 130 63 85 59 
9 123 63 83 79 
10 115 71 86 74 
11 97 51 66 62 
12 102 62 75 69 
13 116 82 93 76 
14 114 64 81 64 
15 112 68 83 80 
16 140 80 100 91 
17 126 66 86 49 
18 121 56 78 63 
19 113 57 76 64 
20 119 74 89 70 
21 121 70 87 80 
22 115 56 76 66 
23 131 76 94 76 
24 109 59 76 72 
25 93 54 67 35 
26 117 63 81 50 
27 111 72 85 58 
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28 119 61 80 68 
29 120 60 80 61 
30 121 64 83 71 
31 111 64 80 57 
32 124 64 84 57 
33 118 58 78 58 
34 130 69 89 66 
35 121 65 84 66 
36 107 64 78 63 
37 127 56 80 65 
38 122 54 77 74 
39 110 60 77 64 
40 112 65 81 76 
41 131 61 84 50 
42 139 71 94 76 
43 108 66 80 57 
44 107 59 75 57 
45 115 66 82 78 
46 141 79 100 67 
47 107 68 81 58 
48 120 66 84 73 
49 112 53 73 65 
50 99 56 70 71 
51 131 69 90 72 
52 120 63 82 67 
53 89 62 71 71 
54 111 62 78 66 
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C.3 Aortic Hemodynamics – Trial 1 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 118 82 98 36 63 
2 101 67 83 34 55 
3 99 63 79 36 44 
4 92 57 73 35 70 
5 108 69 86 39 62 
6 108 63 82 45 62 
7 113 81 97 32 72 
8 104 64 82 40 57 
9 98 64 78 34 75 
10 97 72 86 25 74 
11 77 51 62 26 57 
12 87 63 73 24 65 
13 106 83 94 23 76 
14 95 64 79 31 62 
15 99 70 85 29 72 
16 115 82 96 33 88 
17 102 66 82 36 51 
18 104 56 77 48 63 
19 90 57 72 33 63 
20 107 76 92 31 68 
21 100 72 88 28 83 
22 90 57 72 33 67 
23 110 77 96 33 73 
24 92 61 77 31 69 
25 90 54 68 36 39 
26 88 57 70 31 49 
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27 95 73 85 22 56 
28 96 62 78 34 72 
29 99 60 78 39 64 
30 99 65 83 34 70 
31 98 64 80 34 52 
32 107 65 84 42 57 
33 93 58 72 35 58 
34 105 69 84 36 60 
35 98 66 82 32 67 
36 94 70 83 24 60 
37 98 56 74 42 60 
38 97 55 74 42 72 
39 89 61 73 28 63 
40 99 66 83 33 77 
41 102 61 78 41 52 
42 110 72 89 38 73 
43 99 67 81 32 57 
44 93 60 76 33 59 
45 94 66 79 28 76 
46 126 81 103 45 64 
47 98 68 83 30 56 
48 97 67 81 30 68 
49 87 53 66 34 61 
50 81 57 67 24 66 
51 106 70 87 36 69 
52 98 64 79 34 61 
53 77 62 69 15 71 
54 90 62 74 28 59 
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C.4 Aortic Hemodynamics – Trial 2 
Subject # 
SAP 
(mmHg) 
DAP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
HR 
(bpm) 
1 118 82 98 36 64 
2 101 66 82 35 63 
3 98 63 78 35 45 
4 94 58 76 36 74 
5 108 69 83 39 59 
6 108 63 84 45 60 
7 113 80 97 33 62 
8 105 64 83 41 58 
9 98 64 79 34 78 
10 97 72 85 25 75 
11 77 51 63 26 60 
12 87 63 74 24 67 
13 106 83 94 23 74 
14 95 64 79 31 63 
15 99 69 84 30 77 
16 115 82 96 33 88 
17 101 66 82 35 50 
18 103 57 78 46 67 
19 89 58 72 31 64 
20 110 76 93 34 71 
21 100 71 85 29 75 
22 91 57 73 34 70 
23 109 77 93 32 71 
24 90 60 76 30 70 
25 90 55 70 35 39 
26 88 57 71 31 53 
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27 96 73 85 23 58 
28 96 62 76 34 65 
29 98 61 78 37 70 
30 100 65 83 35 72 
31 101 65 82 36 50 
32 108 64 83 44 58 
33 93 57 70 36 56 
34 104 70 83 34 66 
35 98 65 80 33 66 
36 93 70 82 23 67 
37 98 57 76 41 62 
38 99 54 72 45 60 
39 89 61 73 28 79 
40 102 67 85 35 75 
41 103 61 77 42 54 
42 111 72 90 39 72 
43 99 66 80 33 56 
44 93 60 76 33 58 
45 94 67 81 27 86 
46 125 81 103 44 72 
47 95 68 81 27 60 
48 97 67 82 30 68 
49 87 53 66 34 63 
50 82 57 69 25 67 
51 105 70 86 35 72 
52 97 64 79 33 61 
53 77 62 70 15 72 
54 90 62 75 28 65 
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C.5 Pulse Wave Analysis 
 Trial 1       Trial 2 
Subject # AIx AIx @ 75 AIx AIx @ 75 
1 35 29 36 31 
2 -5 -14 -7 -13 
3 25 10 17 3 
4 5 3 9 9 
5 -12 -18 -14 -22 
6 15 8 15 8 
7 22 20 23 17 
8 -10 -19 5 -4 
9 -6 -6 -7 -6 
10 -1 -1 -5 -6 
11 -11 -20 -12 -19 
12 -5 -10 -7 -10 
13 18 18 17 17 
14 3 -3 5 -1 
15 11 12 14 13 
16 -12 -6 -13 -6 
17 -1 -13 -5 -17 
18 18 12 18 14 
19 3 -2 -2 -8 
20 22 20 25 22 
21 -1 3 -10 -10 
22 -13 -17 -14 -17 
23 5 4 -2 -4 
24 10 7 2 0 
25 34 - 34 - 
26 -17 -30 -15 -26 
27 -1 -10 4 -5 
28 -2 -4 -3 -8 
29 11 6 7 5 
30 3 1 8 7 
31 16 5 28 16 
32 12 4 13 4 
33 -14 -22 -16 -26 
34 -16 -23 -16 -20 
35 -3 -7 -8 -12 
36 14 7 10 7 
37 -1 -9 -4 -7 
38 -4 -6 3 -4 
39 -20 -26 -16 -19 
40 19 19 26 26 
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41 -10 -21 -14 -24 
42 -6 -6 1 2 
43 21 13 21 12 
44 16 8 15 7 
45 -12 -12 -5 1 
46 25 22 24 22 
47 25 16 16 9 
48 -9 -13 -6 -10 
49 -13 -19 -12 -18 
50 -6 -11 -7 -10 
51 -18 -21 -16 -18 
52 -4 -11 1 -6 
53 -2 -4 -5 -6 
54 -9 -17 -12 -17 
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C.6 Pulse Wave Velocity 
 Trial 1 Trial 2 
Subject #  
Velocity  
(m/s) SD 
Velocity 
(m/s) SD 
1 7.9 0.7 7.1 0.5 
2 4.9 0.3 5.7 0.4 
3 5.9 0.5 6 0.2 
4 4.5 0.3 5.1 0.6 
5 5.2 0.4 5.4 0.3 
6 5.2 0.4 4.4 0.3 
7 5.8 0.4 6.1 0.5 
8 5.2 0.5 5 0.5 
9 5.9 0.4 7 0.6 
10 4.1 0.3 5 0.5 
11 3.9 0.3 4.6 0.3 
12 4.5 0.3 5 0.3 
13 7 0.8 7.2 0.6 
14 5.5 0.4 5.6 0.4 
15 5.2 0.3 5.6 0.3 
16 6.6 0.6 7.3 0.4 
17 4.4 0.2 5.6 0.5 
18 5.5 0.5 4.7 0.3 
19 5.2 0.3 5.2 0.4 
20 6 0.6 6.8 0.6 
21 5.3 0.3 5.5 0.3 
22 4.5 0.2 4 0.4 
23 4.7 0.4 4.2 0.2 
24 5.1 0.3 5.2 0.3 
25 5.8 0.4 6.6 0.3 
26 4.5 0.3 5.5 0.4 
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27 5.5 0.5 5.7 0.6 
28 5.1 0.4 4.2 0.3 
29 5.3 0.2 5.1 0.2 
30 4.6 0.2 5.3 0.4 
31 5.2 0.6 5 0.6 
32 5.9 0.5 5.2 0.2 
33 6.8 0.8 6.1 0.6 
34 5.6 0.2 5.2 0.3 
35 5.6 0.5 5.3 0.6 
36 5 0.6 5.9 0.9 
37 6.5 0.6 5.6 0.3 
38 5 0.5 5.1 0.4 
39 4.6 0.5 4.8 0.3 
40 5.1 0.4 5 0.4 
41 5.2 0.4 5.8 0.4 
42 5.2 0.4 6.1 0.5 
43 5.8 0.4 6.5 0.7 
44 6.1 0.7 6 1.1 
45 5.6 0.4 5.5 0.2 
46 7.6 0.5 8 0.4 
47 5.3 0.4 5.7 0.5 
48 4.8 0.2 5.3 0.5 
49 3.6 0.5 3.8 0.5 
50 3.3 0.3 4.2 0.2 
51 5.6 0.3 5.6 0.3 
52 5.2 0.4 5.7 0.5 
53 5.3 0.5 5.7 0.5 
54 5.2 0.3 4.8 0.3 
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C.7 Decentering Questionnaire  
Subject # Decentering Score 
1 32 
2 39 
3 46 
4 48 
5 35 
6 43 
7 40 
8 38 
9 43 
10 44 
11 46 
12 53 
13 37 
14 54 
15 51 
16 44 
17 34 
18 37 
19 26 
20 35 
21 38 
22 43 
23 54 
24 40 
25 33 
26 46 
27 40 
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28 26 
29 38 
30 41 
31 33 
32 37 
33 36 
34 36 
35 32 
36 34 
37 35 
38 41 
39 45 
40 51 
41 35 
42 43 
43 34 
44 39 
45 36 
46 41 
47 37 
48 27 
49 53 
50 48 
51 35 
52 48 
53 40 
54 51 
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Appendix D: Summary Statistics for Study 2 
D.1 Median analysis 
Independent samples t-test 
95% Confidence Interval 
 Mean Lower Upper t df Sig (2-tailed) 
Decentering -11.22222 -13.50009 -8.94435 9.886 52 0.000 
AIx 3.85185 -3.82591 11.52962 1.007 52 0.319 
AIx @ 75 1.05556 -6.49252 8.60363 0.281 52 0.780 
cfPWV 0.51432 0.11718 0.91146 2.600 51 0.012 
 
D.2 Correlations 
  Pearson correlation Sig. (2-tailed) N 
Decentering 1  54 
Aix -0.145 0.296 54 
Aix @ 75 -0.066 0.638 54 
cfPWV -0.349 0.010 53 
 
